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A BS T R AC T
BACKGROUND

Diabetic ketoacidosis in children may cause brain injuries ranging from mild to severe.
Whether intravenous fluids contribute to these injuries has been debated for decades.
METHODS

We conducted a 13-center, randomized, controlled trial that examined the effects of the
rate of administration and the sodium chloride content of intravenous fluids on neurologic outcomes in children with diabetic ketoacidosis. Children were randomly assigned to
one of four treatment groups in a 2-by-2 factorial design (0.9% or 0.45% sodium chloride
content and rapid or slow rate of administration). The primary outcome was a decline in
mental status (two consecutive Glasgow Coma Scale scores of <14, on a scale ranging from
3 to 15, with lower scores indicating worse mental status) during treatment for diabetic
ketoacidosis. Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during treatment for diabetic ketoacidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis.

The authors’ affiliations are listed in the
Appendix. Address reprint requests to
Dr. Kuppermann at the Department of
Emergency Medicine, University of California, Davis, School of Medicine, 2315
Stockton Blvd., Sacramento, CA 95817, or
at nkuppermann@ucdavis.edu.
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the acknowledgments.
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RESULTS

A total of 1389 episodes of diabetic ketoacidosis were reported in 1255 children. The
Glasgow Coma Scale score declined to less than 14 in 48 episodes (3.5%), and clinically
apparent brain injury occurred in 12 episodes (0.9%). No significant differences among the
treatment groups were observed with respect to the percentage of episodes in which the
Glasgow Coma Scale score declined to below 14, the magnitude of decline in the Glasgow
Coma Scale score, or the duration of time in which the Glasgow Coma Scale score was less
than 14; with respect to the results of the tests of short-term memory; or with respect to
the incidence of clinically apparent brain injury during treatment for diabetic ketoacidosis.
Memory and IQ scores obtained after the children’s recovery from diabetic ketoacidosis also
did not differ significantly among the groups. Serious adverse events other than altered
mental status were rare and occurred with similar frequency in all treatment groups.
CONCLUSIONS

Neither the rate of administration nor the sodium chloride content of intravenous fluids
significantly influenced neurologic outcomes in children with diabetic ketoacidosis.
(Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human
Development and the Health Resources and Services Administration; PECARN DKA
FLUID ClinicalTrials.gov number, NCT00629707.)
n engl j med 378;24
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linically apparent brain injuries
occur in 0.5 to 0.9% of episodes of diabetic ketoacidosis in children; these brain
injuries manifest as sudden neurologic decline
and are often associated with morbidity and
mortality.1-3 Among patients without obvious neurologic decline during treatment for diabetic
ketoacidosis, subtle neurologic alterations are
often present after recovery, including deficits in
memory, attention, and IQ4-7 and changes in cerebral microstructure.4,8,9
Early theories to explain diabetic ketoacidosis–
related brain injury suggested that rapid administration of intravenous fluids reduces serum
osmolality, which results in brain swelling.10,11
Therefore, many treatment protocols for diabetic
ketoacidosis in children advocate slow rehydration with isotonic fluids. Retrospective reviews
have been used to support these strategies; however, those studies are subject to bias owing to
the higher rates of brain injury that have been
seen in children who are more dehydrated2 and
therefore receive larger volumes of fluid. In addition, such studies have often included patients
who had been selectively referred because of the
severity of their illness from facilities that were
often not specifically pediatric centers and that
used treatment protocols that differed from those
at pediatric centers.10,12,13 Rates of clinically apparent brain injury have remained stable over
time,2,14,15 and properly controlled retrospective
studies have not shown associations between the
fluid administration rate and brain injury.2,3 Instead, data suggest that brain injury may result
from abnormalities in cerebral perfusion and
inflammation that occur during episodes of diabetic ketoacidosis.2,16 In the current trial, we investigated the effects of specific intravenous fluid
regimens on neurologic outcomes in children
with diabetic ketoacidosis.

m e dic i n e

of rehydration rate and fluid sodium chloride
content on neurocognitive outcomes, including
neurologic status during the episode of diabetic
ketoacidosis and memory and IQ after recovery
from diabetic ketoacidosis. Details of the trial
methods were published previously17 and are
also provided in the protocol, available with the
full text of this article at NEJM.org.
Trial Oversight

The trial was designed by the first and last authors (principal investigators), with input from
site investigators; collaborators from the PECARN
data coordinating center; the PECARN quality,
safety, and regulatory affairs subcommittee; the
PECARN protocol review and development subcommittee; and the PECARN grant writing and
publications subcommittee. Research coordinators collected the data under the supervision of
the site investigators. The PECARN data coordinating center was responsible for data quality
control and analyses. A data and safety monitoring board, which oversaw the conduct of the
trial, included an expert in each of the following
disciplines: emergency medicine, pediatric critical care, pediatric endocrinology, neuropsychology, and biostatistics. The data and safety monitoring board convened before enrollment, at the
time of three scheduled interim efficacy analyses, and at the time of four additional scheduled
reviews of safety, enrollment, and follow-up data.
The authors vouch for the accuracy and completeness of the data and analyses and for the
fidelity of the trial to the protocol. There was no
industry funding for this trial, and there were
no agreements concerning confidentiality of the
data between the sponsor and the authors or institutions. All the authors reviewed drafts of the
manuscript and agreed with the decision to submit the manuscript for publication.
Patients

Me thods
Overview of the Trial

We conducted this randomized, controlled trial
at 13 emergency departments in the Pediatric
Emergency Care Applied Research Network
(PECARN), all of which were located in urban
centers in the United States. We used a 2-by-2
factorial design to compare four rehydration
treatment regimens in children with diabetic
ketoacidosis (Table 1).17 We evaluated the effects
2276
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Children were eligible for enrollment in the trial
if they were between 0 and 18 years of age and
had received a diagnosis of diabetic ketoacidosis
(defined as a blood glucose level of >300 mg
per deciliter [16.7 mmol per liter] and either a
venous pH of <7.25 or a serum bicarbonate level
of <15 mmol per liter). Key exclusion criteria17
were underlying disorders that could affect mental status testing or neurocognitive evaluation;
concurrent alcohol or narcotics use, head trauma,
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0.9% sodium chloride solution
0.45% sodium chloride solution

*	Initial fluid bolus volumes were subtracted from the fluid deficit that was used to calculate the rate of fluid replacement. Fluid boluses could be repeated at the discretion of the treating
physician to restore peripheral perfusion and hemodynamic stability. Insulin treatment was initiated after the initial intravenous fluid boluses as a continuous intravenous infusion at a
rate of 0.1 U per kilogram of body weight per hour. Dextrose was added to the intravenous fluids when the serum glucose level declined to below 200 to 300 mg per deciliter (11.1 to
16.7 mmol per liter) to maintain the serum glucose level between 100 and 200 mg per deciliter (5.6 to 11.1 mmol per liter).
†	Replacement of potassium was provided with the use of an equal mixture of potassium chloride and potassium phosphate or an equal mixture of potassium acetate and potassium
phosphate. Potassium salts used for replacement were identical among the groups at each site but varied among the trial sites.

10% of body weight

0.9% sodium chloride solution
0.45% sodium chloride solution
Fluid used for replacement of deficit†

5% of body weight
10% of body weight

During the initial 12 hours, replace During the initial 12 hours, replace Replace deficit, plus maintenance Replace deficit, plus maintenance
half the fluid deficit, plus mainhalf the fluid deficit, plus mainfluids, evenly during a period of
fluids, evenly during a period of
tenance fluids. Then replace retenance fluids. Then replace re48 hours.
48 hours.
maining deficit, plus maintemaining deficit, plus maintenance fluids, during the subsenance fluids, during the subsequent 24 hours.
quent 24 hours.

Assumed fluid deficit

Process for replacement of deficit

June 14, 2018

5% of body weight

No additional bolus
10 ml per kilogram of 0.9% sodium 10 ml per kilogram of 0.9% sodium No additional bolus
chloride solution
chloride solution

10 ml per kilogram bolus of 0.9%
sodium chloride solution

10 ml per kilogram bolus of 0.9%
sodium chloride solution

10 ml per kilogram bolus of 0.9%
sodium chloride solution

Additional intravenous fluid bolus

Fast Administration of 0.45%
Sodium Chloride Solution

nejm.org

Variable

Table 1. Treatment Regimens.

Written informed consent was obtained from
the parents or guardians of all enrolled patients.
Assent was obtained from patients whose age
met the minimum age for assent according to
their local institutional review board. Children
were then randomly assigned to one of four
treatment regimens: fast rate of rehydration with
fluid that had 0.45% sodium chloride content,
fast rate of rehydration with fluid that had 0.9%
sodium chloride content, slow rate of rehydration with fluid that had 0.45% sodium chloride
content, and slow rate of rehydration with fluid
that had 0.9% sodium chloride content. Details of
the treatment regimens are provided in Table 1.
Randomization was stratified according to baseline Glasgow Coma Scale score (14 or 15 vs. <14)
and center (if the Glasgow Coma Scale score was
<14).17 To avoid excessive restriction of the population available for enrollment, patients who had
previously undergone randomization and subsequently had another episode of diabetic ketoacidosis during the trial were eligible to undergo
randomization a second time. A patient could
undergo randomization no more than twice. Additional details are provided in the Statistical
Analysis section and in the protocol.
Treatment for diabetic ketoacidosis other than
the rate of administration and the sodium chloride content of the fluid was identical in the four
treatment groups.17 After administration of intravenous fluid boluses, insulin treatment was
initiated as a continuous intravenous infusion at
a rate of 0.1 U per kilogram of body weight per
hour. To prevent hypoglycemia during insulin
treatment, dextrose was added to the study fluids
when the serum glucose level declined below
200 to 300 mg per deciliter (11.1 to 16.7 mmol

Fast Administration of 0.9%
Sodium Chloride Solution

Treatments

10 ml per kilogram bolus of 0.9%
sodium chloride solution

Slow Administration of 0.45%
Sodium Chloride Solution

Slow Administration of 0.9%
Sodium Chloride Solution

or other conditions that could affect neurologic
function; diabetic ketoacidosis for which the patient had already received substantial treatment;
known pregnancy; or factors for which treating
physicians determined that a specific fluid and
electrolyte therapy was necessary. Children who
presented with a Glasgow Coma Scale score of
11 or lower (on a scale ranging from 3 to 15,
with lower scores indicating worse mental status) were excluded after year 2 because many
participating clinicians believed that fluid regimens for such children should not be determined on the basis of randomization.

Standard initial fluid bolus*

Fluid Infusion for Pediatric Diabetic Ketoacidosis
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conducted at enrollment and every 4 hours
thereafter during normal waking hours. Glasgow
Coma Scale and digit-span assessments continued for 24 hours or until resolution of diabetic
ketoacidosis (as defined by the transition to
subcutaneous insulin) if diabetic ketoacidosis
resolved before the 24-hour time point.

Outcomes

The primary trial outcome was deterioration of
neurologic status (as evidenced by two consecutive Glasgow Coma Scale scores of <14 during
any hour within the first 24 hours of treatment
for diabetic ketoacidosis). Secondary outcomes
included short-term memory during treatment
for diabetic ketoacidosis (forward and backward
digit-span recall; scores range from 0 to 16, with
higher scores indicating better short-term memory)18; clinically apparent brain injury (defined as
a deterioration in neurologic status leading to
initiation of hyperosmolar therapy or endotracheal intubation or resulting in death) during
treatment for diabetic ketoacidosis; and shortterm memory, contextual memory, and IQ 2 to
6 months after the episode of diabetic ketoacidosis. In the digit span test, participants are asked
to repeat a sequence of numbers presented orally.
In the “forward” task, participants are asked to
repeat numbers in order, as presented. In the
“backward” task, participants are asked to list
the numbers in reverse order. The test stops
when participants report the incorrect sequence
twice for a given digit-span length.
To address variations in the diagnosis of
clinically apparent brain injury, records of encounters with patients in which hyperosmolar
therapy, endotracheal intubation, or death were
documented were reviewed by an adjudication
committee that included two pediatric critical
care physicians and one pediatric emergency
medicine physician, all of whom were unaware
of the treatment-group assignments. Committee
members confirmed or rejected each diagnosis
of clinically apparent brain injury on the basis of
published criteria.19
Assessments

Assessments of Mental Status

Glasgow Coma Scale scores were assessed at
enrollment and hourly thereafter. Glasgow Coma
Scale scores of less than 14 were confirmed by
repeating the test 15 minutes later. For children
3 years of age or older, digit-span tests were
2278
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Assessments of Memory Function and IQ

Patients 3 to 18 years of age were asked to return
2 to 4 months after discharge from the hospital
for neurocognitive assessment but were allowed
to return up to 6 months after discharge. Neurocognitive testing was rescheduled in the event of
either hypoglycemia (defined as a glucose level
of <70 mg per deciliter [3.9 mmol per liter]) or
ketosis (defined as the presence of moderate or
large urine ketones).
IQ was evaluated with the use of the Wechsler
Abbreviated Scale of Intelligence20 (in patients
6 years of age or older) and the Wechsler Preschool and Primary Scale of Intelligence short
form (in patients 3 to 5 years of age).21 At the
same testing session, the digit-span test was repeated, and contextual memory was assessed
with color and spatial-position tasks,17 which
evaluated item recognition and recollection of
contextual detail. Shorter and simpler versions
of these tasks were used for children 3 to 5 years
of age.17 Research personnel who conducted the
cognitive testing and recorded outcome data were
unaware of the treatment-group assignments, as
were the trial investigators who oversaw this
process.
Statistical Analysis

The primary analyses were performed according
to the intention-to-treat principle. We also performed secondary analyses in the per-protocol
population (which included patients who underwent randomization and received trial fluids per
the protocol) and in the safety population (which
included all patients who received any trial fluid)
(details are provided in the protocol). Patients
who had Glasgow Coma Scale scores of 14 or 15
at baseline were included in the primary analyses. Because patients who had Glasgow Coma
Scale scores of less than 14 at baseline had already met the criterion for the primary outcome
before enrollment, such patients were not included in the primary analyses but were included
in the secondary analyses. Distinct encounters
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with the same patient were considered to be independent events. Given that patients who underwent randomization a second time could have
been randomly assigned to a treatment regimen
that was different from the first regimen they
had been assigned to, a single patient could be
represented in more than one treatment group
in the analyses. Cochran–Mantel–Haenszel tests
were used to test the effects of the rate of administration and of the sodium chloride content of the fluid. Each of these factors was
tested with the use of P values that were adjusted for multiplicity at a two-sided alpha level
of 0.025.
We analyzed the magnitude of the decline in
the Glasgow Coma Scale score and the duration
of time in which the Glasgow Coma Scale score
was less than 14 using Van Elteren tests, with
adjustment for stratification variables. The incidence of clinically apparent brain injury was
evaluated with the use of a Cochran–Mantel–
Haenszel test. We tested for treatment interactions using regression models. To evaluate digitspan scores, we used a linear mixed-effects
model to estimate time-dependent effects of the
rate of administration and the sodium chloride
content of the fluid. We assigned a digit-span
score of zero in cases in which a patient had a
Glasgow Coma Scale score of less than 14 to
account for digit-span scores that could not be
measured owing to mental status alterations.
A random intercept and slope term for patient
encounters and similar fixed terms for trial centers were included in the model.
The main analysis of memory function was
based on the average of the children’s correct
recall rates of items in association with their
color background or spatial location. Scores were
excluded from the analysis if chance recognition
of previously viewed items was observed (sensitivity index of <0.50; 5% of tests). Memory scores
and IQ were compared with the use of a Van
Elteren test, with adjustment for stratification
variables. In cases in which a patient had more
than one valid follow-up measurement, only the
first measurement was included in the analysis.
Significance levels for digit-span score and memory function were adjusted for multiple comparisons with the use of the Holm procedure.
We also analyzed treatment effects in prespecified subgroups defined according to age
(<6 years vs. ≥6 years), Glasgow Coma Scale score
n engl j med 378;24

at baseline, and history of diabetic ketoacidosis
(yes vs. no) using regression models, with adjustment for stratification variables. The overall
type I error rate for the subgroup analyses was
preserved at 0.05. Using the same methods, we
explored treatment effects in eight subgroups
defined according to various baseline characteristics that are associated with more severe diabetic ketoacidosis; results from four of these subgroups are reported and should be interpreted
with caution owing to multiple comparisons.
The analyses of statistical power and sample
size have been described previously.17 Our target
sample size was 1360 patient encounters involving children who had baseline Glasgow Coma
Scale scores of 14 or 15 (i.e., 1360 episodes of
diabetic ketoacidosis that could be included in the
primary analysis).
Two-sided O’Brien–Fleming stopping boundaries at the time of each interim efficacy analysis
were calculated with the use of the alpha-spending function approach. The thresholds for significance at the first, second, and third interim
analyses were 0.000006, 0.0008, and 0.0075, respectively. No safety concerns were identified,
and the trial proceeded to completion.

R e sult s
Patients

From February 2011 through September 2016, a
total of 1255 children were randomly assigned
to one of the four treatment regimens (Table 1).
Among these 1255 patients, 132 had a second
episode of diabetic ketoacidosis and underwent
randomization a second time during the trial.
Two additional patients who had a third episode
of diabetic ketoacidosis inadvertently underwent
randomization a third time. Therefore, a total of
1389 distinct episodes of diabetic ketoacidosis
were evaluated. Patient enrollment and randomization status are shown in Figure 1. Demographic and clinical characteristics of the children, including status with respect to history of
diabetes, did not differ significantly among the
four groups (Table 2). Adherence to the assigned
treatment regimens was excellent (Figs. S1 and
S2 in the Supplementary Appendix, available at
NEJM.org). Enrollment varied among the emergency departments; the number of patient encounters ranged from 23 to 239 (Table S1 in the
Supplementary Appendix).
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4912 Patients met inclusion criteria

2064 Were ineligible
1377 Were transferred from another facility where they
received an initial fluid bolus of >10 ml/kg
527 Received intravenous fluids at a maintenance rate
or greater for >2 hr
410 Received treatment for diabetic ketoacidosis >4 hr
before eligibility assessment
289 Were withdrawn by physician
101 Were enrolled more than once previously
90 Had preexisting neurologic disease
67 Had a Glasgow Coma Scale score of ≤11
42 Were scheduled to receive or had already received
hyperosmolar therapy
28 Had concurrent alcohol or drug use, head
trauma, meningitis, or other condition affecting
mental status
2 Were pregnant

2848 Were eligible

631 Were not approached
272 Were unable to undergo randomization
within the eligibility time window
264 Were unable to be enrolled owing to lack
of availability of research staff
95 Were not approached for other reasons

2217 Were approached

812 Had guardian who did not give consent

1405 Consented

16 Did not undergo randomization

1389 Underwent randomization

344 Were assigned to fast administration rate and 0.45% sodium
chloride content
337 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment

351 Were assigned to fast administration rate and 0.9% sodium
chloride content
345 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment

345 Were assigned to slow administration rate and 0.45% sodium
chloride content
338 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment

349 Were assigned to slow administration rate and 0.9% sodium
chloride content
341 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment

therefore included in the primary analysis. During the course of the trial, the Glasgow Coma
In 1361 episodes of diabetic ketoacidosis (98.0%), Scale score declined to below 14 in 48 (3.5%) of
children presented with Glasgow Coma Scale these episodes (Table 3). A total of 22 episodes
scores of 14 or 15, and these episodes were (1.6%) resulted in the children receiving hyper-

Mental Status during Treatment for Diabetic
Ketoacidosis
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Subgroup Analyses of Mental Status

Figure 1 (facing page). Enrollment and Randomization.
A total of 586 patients met multiple ineligibility criteria.
Three patients who had a Glasgow Coma Scale score
of 11 or lower were enrolled before the implementation
of this exclusion criterion. Patients were permitted to
undergo randomization a second time if they had a second episode of diabetic ketoacidosis during the trial, with
each randomization considered to be a distinct encounter; hence, some children are represented more than
once in this figure. A total of 1255 patients underwent
randomization initially. Among these 1255 patients,
132 had a second episode of diabetic ketoacidosis and
underwent randomization a second time during the trial.
Two additional patients who had a third episode of diabetic ketoacidosis inadvertently underwent randomization a third time. Therefore, a total of 1389 distinct episodes of diabetic ketoacidosis were evaluated, as shown
here. Enrollment sites were located in Boston, MA, Chicago, IL, Columbus, OH, Denver, CO, Houston, TX, New
York, NY, Philadelphia, PA, Providence, RI, Sacramento,
CA, Salt Lake City, UT, St. Louis, MO, Washington, DC,
and Wilmington, DE.

osmolar therapy for possible cerebral edema or
brain injury. In 12 episodes (0.9%), the children
had clinically apparent brain injury (confirmed
by adjudication) — a rate that was similar to previously documented frequencies.1-3 Most of the 12
patients presented with severe acidosis and hypocapnia (Table S2 in the Supplementary Appendix).
One of the 12 patients died, and the remaining
patients recovered without overt neurologic
deficits.
There were no significant differences among
the groups in the percentage of episodes in
which the Glasgow Coma Scale score declined to
below 14, in the magnitude of decline in the
Glasgow Coma Scale score, or in the duration of
time in which the Glasgow Coma Scale score
was less than 14 (Table 3, and Table S3 in the
Supplementary Appendix). The Breslow–Day test
for homogeneity of the odds ratios did not provide evidence against homogeneity (P = 0.39 for
administration rate; P = 0.67 for sodium chloride
content). The incidence of clinically apparent
brain injury was higher in the slow rehydration
groups than in the fast rehydration groups; however, the differences were not significant. Digitspan scores during the episode of diabetic ketoacidosis did not differ significantly among the
four groups, although point estimates for the
rate of improvement in forward digit-span scores
favored more rapid rehydration (P = 0.06).

n engl j med 378;24

Analyses of the relative risk of a decline to below
14 in the Glasgow Coma Scale score in subgroups defined according to age and history of
diabetic ketoacidosis among patients who had
Glasgow Coma Scale scores of 14 or 15 at baseline did not show differential treatment effects
(Fig. S3 in the Supplementary Appendix). In the
subgroups of patients who had more severe diabetic ketoacidosis (a pH or partial pressure of
carbon dioxide [Pco2] level in the lowest quartile
or a blood urea nitrogen level or glucose level in
the highest quartile), the percentage of episodes
in which the Glasgow Coma Scale score declined
to below 14 and the percentage of episodes in
which clinically apparent brain injury was confirmed did not differ significantly among the
groups (Table S4 in the Supplementary Appendix). The effect of rehydration rate on forward
digit-span scores differed in the subgroup defined
according to Pco2 level (P = 0.03 for the interaction between treatment and Pco2 level), with faster
improvement in the rapid rehydration groups
than in the slow rehydration groups among patients with a low Pco2 level (P = 0.03). The effect
of rehydration rate on backward digit-span scores
differed in the subgroup defined according to
pH level (P = 0.01 for the interaction between
treatment and pH level), with faster improvement in the rapid rehydration groups than in the
slow rehydration groups among patients with a
low pH (P = 0.01).
Neurocognitive Assessments after Recovery
from Diabetic Ketoacidosis

In all, 1287 episodes occurred in children older
than 3 years of age who met the criteria for
follow-up neurocognitive testing. The children
involved in 387 of these episodes (30.1%) were
either lost to follow-up or declined to return for
neurocognitive testing (see “Power and Sample
Size” in the Supplementary Appendix for sensitivity analyses regarding missing data). Data were
analyzed for 855 episodes (66.4%), for which
follow-up occurred within 6 months after the
patient’s discharge from the hospital (756 within 4 months and 99 between 5 and 6 months).
There were no significant differences in neurocognitive outcomes after recovery among the
trial groups (Table S5 in the Supplementary Appendix).
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peated the analyses to determine whether these
protocol deviations influenced the outcomes
Fluid hydration regimens that were administered (Tables S6 and S7 in the Supplementary Appenin 115 episodes (8.3%), including 107 (7.9%) dix). The results of these analyses showed no
analyzed for the primary outcome, deviated suf- significant differences among the groups.
ficiently from the assigned treatment regimen
that the rate of administration or sodium chlo- Results among Patients According to
ride content of the fluid was more similar to Treatment Received
other treatment regimens than to the assigned We modeled continuous versions of fluid adminregimen. We excluded these episodes and re- istration rate and sodium chloride content in

Results among Patients Treated According to
the Protocol

Table 2. Demographic and Clinical Characteristics of the Trial Population.*

Variable

Fast Administration
of 0.45% Sodium
Chloride Solution
(N = 344)

Fast Administration
of 0.9% Sodium
Chloride Solution
(N = 351)

Slow Administration
of 0.45% Sodium
Chloride Solution
(N = 345)

Slow Administration
of 0.9% Sodium
Chloride Solution
(N = 349)

11.5±4.06

11.8±4.26

11.6±4.09

11.6±3.89

Demographic characteristics
Age — yr
Age <6 yr — no. (%)

43 (12.5)

42 (12.0)

42 (12.2)

35 (10.0)

White

235/327 (71.9)

232/328 (70.7)

247/331 (74.6)

243/329 (73.9)

Black

73/327 (22.3)

82/328 (25.0)

68/331 (20.5)

63/329 (19.1)

Race — no./total no. (%)†

Other
Hispanic ethnic group — no./total no. (%)†

19/327 (5.8)

14/328 (4.3)

16/331 (4.8)

23/329 (7.0)

48/331 (14.5)

62/335 (18.5)

49/329 (14.9)

69/342 (20.2)

165 (48.0)

164 (46.7)

158 (45.8)

163 (46.7)

Male sex — no. (%)
Diabetes history
Previous diagnosis of diabetes — no. (%)

174 (50.6)

Duration of diabetes — yr

182 (51.9)

185 (53.6)

192 (55.0)

4.8±3.1

5.1±3.2

4.9±3.4

4.8±3.3

135/170 (79.4)

139/178 (78.1)

144/183 (78.7)

154/188 (81.9)

1 or 2 episodes

20/170 (11.8)

26/178 (14.6)

29/183 (15.8)

25/188 (13.3)

>2 episodes

15/170 (8.8)

13/178 (7.3)

10/183 (5.5)

9/188 (4.8)

42/173 (24.3)

34/181 (18.8)

60/182 (33.0)

58/189 (30.7)

History of severe hypoglycemia — no./total no. (%)
None

Previous episodes of diabetic ketoacidosis
among patients with known diabetes
— no./total no. (%)
None
1 or 2

74/173 (42.8)

83/181 (45.9)

67/182 (36.8)

77/189 (40.7)

>2

57/173 (32.9)

64/181 (35.4)

55/182 (30.2)

54/189 (28.6)

10.6±2.0

10.8±1.8

10.7±1.9

10.5±2.0

Glycated hemoglobin level in previous yr — %‡
Mental status at randomization
Glasgow Coma Scale score at randomization — no. (%)§
<14

7 (2.0)

6 (1.7)

7 (2.0)

8 (2.3)

14

23 (6.7)

25 (7.1)

26 (7.5)

25 (7.2)

15

314 (91.3)

320 (91.2)

312 (90.4)

316 (90.5)

Forward digit-span recall¶

7.13±2.39

7.12±2.28

7.25±2.07

7.46±2.37

Backward digit-span recall¶

5.54±2.31

5.47±2.25

5.51±2.30

5.76±2.31

2282

n engl j med 378;24

nejm.org

June 14, 2018

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 19, 2018. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

Fluid Infusion for Pediatric Diabetic Ketoacidosis

Table 2. (Continued.)
Fast Administration
of 0.45% Sodium
Chloride Solution
(N = 344)

Fast Administration
of 0.9% Sodium
Chloride Solution
(N = 351)

Slow Administration
of 0.45% Sodium
Chloride Solution
(N = 345)

Slow Administration
of 0.9% Sodium
Chloride Solution
(N = 349)

519±153

524±150

523±170

522±156

17±8

17±7

17±9

17±7

pH

7.17±0.09

7.16±0.10

7.16±0.10

7.16±0.11

Sodium — mmol/liter

134±5

134±5

134±5

134±5

Variable
Laboratory values at presentation
Glucose — mg/dl
Blood urea nitrogen — mg/dl

Bicarbonate — mmol/liter
Pco2 — mm Hg

9±3

9±3

9±3

9±3

26±7

26±7

26±8

27±7

*	Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the groups in any of the comparisons according
to Kruskal–Wallis tests for continuous variables and chi-square tests for categorical variables. Patients were permitted to undergo randomization a second time if they had a second episode of diabetic ketoacidosis during the trial, with each randomization considered to be a distinct encounter; therefore, a patient could be represented in more than one group. A total of 132 patients had a second episode of diabetic
ketoacidosis and underwent randomization a second time during the trial. Two additional patients who had a third episode of diabetic ketoacidosis inadvertently underwent randomization a third time. Therefore, a total of 1389 distinct episodes of diabetic ketoacidosis were evaluated Data shown are based on encounters. Percentages may not sum to 100 because of rounding. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357.
†	Race and ethnic group were determined by either patient report or review of medical records.
‡	Data were available for 173, 173, 177, and 184 patients in the four listed groups, respectively.
§	Scores range from 3 to 15, with lower scores indicating worse mental status.
¶	Scores range from 0 to 16, with higher scores indicating better short-term memory. In the digit span test, participants are asked to repeat a
sequence of numbers presented orally. In the “forward” task, participants are asked to repeat numbers in order, as presented. In the “backward” task, participants are asked to list the numbers in reverse order. The test stops when participants report the incorrect sequence twice
for a given digit-span length.

regression analyses. To account for influences of
clinical presentation on decisions of the clinicians to deviate from assigned treatment regimens, we included covariates that reflected the
severity of diabetic ketoacidosis (levels of pH,
Pco2, glucose, sodium, and blood urea nitrogen),
age, and whether the diabetes was new-onset or
preexisting. Again, no significant effects of either
fluid administration rate or sodium chloride content on acute neurologic outcomes were found
(data not shown).

administration was associated with a higher incidence of hypocalcemia but not a higher incidence of hypophosphatemia. Hypoglycemia and
hypokalemia occurred at similar rates in the four
groups. Serious adverse events occurred in less
than 3% of participants (Table 4, and Table S9
in the Supplementary Appendix). The time to
resolution of diabetic ketoacidosis and the duration of hospitalization were similar among the
groups (Table S10 in the Supplementary Appendix).

Discussion

Nonneurologic Adverse Events

Hyperchloremic acidosis was more common
among patients who received fluid that had a
0.9% sodium chloride content than among those
who received fluid that had a 0.45% sodium
chloride content and more common among patients who received fluid at a rapid rate than
among those who received fluid at a slow rate
(Table S8 in the Supplementary Appendix). The
0.9% sodium chloride regimens were also associated with a higher incidence of hypocalcemia
and hypophosphatemia than were the 0.45%
sodium chloride regimens. A rapid rate of fluid
n engl j med 378;24

In this randomized, controlled trial, with a 2-by-2
factorial design, that involved children with diabetic ketoacidosis, there were no significant differences in the rate of decline in mental status
or in the rate of clinically apparent brain injury
during treatment for diabetic ketoacidosis or in
neurocognitive function after recovery from diabetic ketoacidosis among patients who received
rehydration fluid at two different administration
rates and with two different sodium chloride
contents. The lowest rates of mental status decline and clinically apparent brain injury were in
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0.065±0.010
0.052±0.009

Digit-span recall test, forward
slope¶

n engl j med 378;24

Digit-span recall test, backward
slope¶

nejm.org

0.053±0.009

0.058±0.010

2 (0.6)

351

11 (3.2)

345

Fast
Administration
of 0.9%
Sodium Chloride
Solution

0.042±0.009

0.046±0.010

5 (1.4)

345

11 (3.3)

338

Slow
Administration
of 0.45%
Sodium Chloride
Solution

0.043±0.009

0.039±0.010

3 (0.9)

349

16 (4.7)

341

Slow
Administration
of 0.9%
Sodium Chloride
Solution

0.49
(0.15–1.64)

0.76
(0.44–1.33)

Relative Risk
(95% CI)

0.29

0.06

0.24

0.34

P Value

Fast vs. Slow Administration

1.43
(0.46–4.40)

0.80
(0.46–1.40)

Relative Risk
(95% CI)

0.91

0.49

0.53

0.43

P Value

0.45% vs. 0.9% Sodium
Chloride Solution

1.00

0.76

P Value for
Interaction

n e w e ng l a n d j o u r na l
of

*	Plus–minus values are means ±SE. Owing to the factorial nature of the trial, each patient is included in the comparisons of both administration rate and sodium chloride content.
†	The data from 28 patients who had a baseline Glasgow Coma Scale score of less than 14 were excluded from the primary analysis and included in the secondary analyses.
‡	The results of this analysis were compared with the use of a Cochran–Mantel–Haenszel test stratified according to sodium chloride content (comparisons of fast vs. slow administration rate), administration rate (comparisons of 0.45% vs. 0.9% sodium chloride content), and trial site.
§	These patients received mannitol, hypertonic saline, or endotracheal intubation after randomization, and an adjudication committee deemed each patient to have had clinically apparent
brain injury.
¶	Digit-span outcomes (scores ranging from 0 to 16, with higher scores indicating better short-term memory) over time were compared with the use of a mixed linear regression model
with random patient-level intercept and slope terms and included fixed effects for trial site, time, and fluid administration rate and sodium chloride content. In cases in which a patient
had a Glasgow Coma Scale score of less than 14, a digit span of zero was included in the accompanying 4-hour time interval. The digit-span results reported in this table refer to the
slope parameter of the statistical model.

2 (0.6)

344

10 (3.0)

337

Clinically apparent brain injury
— no. (%)‡§

No. of episodes

Secondary outcomes†

Confirmed decline in Glasgow
Coma Scale score to <14
— no. (%)‡

No. of episodes†

Primary outcome

Outcome

Fast
Administration
of 0.45%
Sodium Chloride
Solution

Table 3. Mental Status Changes during Treatment for Diabetic Ketoacidosis.*
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Table 4. Adverse Events.*
Fast Administration
of 0.45%
Sodium Chloride
Solution

Variable
Any adverse event — no. of episodes
Serious adverse event — no. (%)

Fast Administration
of 0.9%
Sodium Chloride
Solution

Slow Administration
of 0.45%
Sodium Chloride
Solution

Slow Administration
of 0.9%
Sodium Chloride
Solution

114

124

118

129

5 (4.4)

4 (3.2)

11 (9.3)

10 (7.8)

102 (89.5)

109 (87.9)

108 (91.5)

118 (91.5)

Outcome — no. (%)
Recovery, with return to baseline
status
Recovery with sequelae

1 (0.9)

1 (0.8)

1 (0.8)

1 (0.8)

10 (8.8)

14 (11.3)

9 (7.6)

10 (7.8)

1 (0.9)

0

0

0

Mild

95 (83.3)

96 (77.4)

89 (75.4)

98 (76.0)

Moderate

12 (10.5)

25 (20.2)

22 (18.6)

30 (23.3)

7 (6.1)

3 (2.4)

7 (5.9)

1 (0.8)

58 (50.9)

56 (45.2)

64 (54.2)

68 (52.7)

Persistence of symptoms
Death
Severity — no. (%)

Severe
Expected event — no. (%)
Common clinical adverse events
— no. (%)†
Headache

29 (25.4)

16 (12.9)

23 (19.5)

28 (21.7)

Oropharyngeal pain

9 (7.9)

11 (8.9)

10 (8.5)

9 (7.0)

Pyrexia

8 (7.0)

11 (8.9)

8 (6.8)

10 (7.8)

Abdominal pain

2 (1.8)

11 (8.9)

7 (5.9)

3 (2.3)

Constipation

3 (2.6)

4 (3.2)

2 (1.7)

11 (8.5)

*	These data were analyzed in the safety population (all patients who underwent randomization and received any trial fluid). Because patients
were permitted to undergo randomization twice, a patient could be represented in more than one group. Data are based on patient encounters (i.e., episodes of diabetic ketoacidoses) rather than on individual patients. An episode in which multiple adverse events of the same
type occurred is counted once. An episode in which multiple adverse events of different types occurred is counted once for each type of
adverse event. In cases in which multiple adverse events occurred in an episode, the most serious adverse event was used to describe
seriousness, outcome, and severity.
†	Common clinical adverse events were events that were reported in six or more patients in any group, excluding adverse events that were
counted either as trial outcomes (mental status changes or brain injuries) or as expected nonneurologic adverse events (e.g., hypoglycemia
or electrolyte abnormalities) (Table S8 in the Supplementary Appendix).

the rapid-rehydration groups, although the differences from other groups were not significant.
Furthermore, analyses of the subgroups of patients who had more severe diabetic ketoacidosis
suggested faster improvement in digit-span recall
in the rapid fluid-administration groups than in
the slow fluid-administration groups. These findings underscore the lack of a causal association
between rapid fluid administration and diabetic
ketoacidosis–related brain injury.
Clinically apparent diabetic ketoacidosis–related
brain injury occurs infrequently but is an important cause of neurologic damage and death
among children with diabetes.1-3,22-24 Subtle brain
injury often occurs during treatment for diabetic
n engl j med 378;24

ketoacidosis in children and may contribute to
cognitive decline.4-9 Excessive fluid administration, which may result in rapid osmotic changes, has been widely suspected to cause brain in
jury,11,25,26 but a more recent hypothesis suggests
that cerebral hypoperfusion and the effects of
reperfusion, along with neuroinflammation, are
central to diabetic ketoacidosis–related brain
injury.2,27-29 The latter hypothesis is consistent
with reports that document symptomatic and
even fatal brain injury occurring before the initiation of treatment for diabetic ketoacidosis.2,30
Furthermore, although cerebral edema is a feature of clinically apparent brain injury, edema
often develops hours or days after a diagnosis of
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brain injury,19 a finding that suggests that edema
may be a consequence, rather than the cause, of
brain injury.
Studies involving children with diabetic ketoacidosis and studies in rodent models suggest
similarities between diabetic ketoacidosis–related
brain injury and ischemia–reperfusion injury.
These include low cerebral blood flow and braincell swelling, along with low levels of high-energy
phosphates in the brain and elevated lactate
levels, during untreated episodes of diabetic ketoacidosis and cerebral hyperemia and vasogenic
edema during treatment for diabetic ketoacidosis.27-29,31-33 Although alterations in cerebral blood
flow may be involved in diabetic ketoacidosis–
related brain injury, the severity of cerebral hypoperfusion is unlikely to be sufficient to cause
brain injury in the absence of other contributing
factors. Diabetic ketoacidosis is associated with
marked systemic increases in inflammatory cytokines and chemokines that may contribute to
brain injury by activating cerebrovascular endothelia and increasing leukocyte adhesion.16,34-36
Elevated levels of matrix metalloproteinase may
promote blood–brain barrier dysfunction.37
The current trial has several limitations. First,
the fluid administration rates were selected to
represent upper and lower boundaries of current
protocols used to treat pediatric diabetic ketoacidosis. It is possible that the use of administration rates outside this range may have resulted in
different outcomes. However, given that the
lowest rate of decline in mental status occurred
in the group that received rapid rehydration with
0.45% sodium chloride solution, it seems unlikely that larger differences between protocols
would have instead favored slower rehydration.
Second, clinically apparent brain injury occurs
in less than 1% of episodes, making it impractical to design a trial with sufficient statistical
power to detect differences in this outcome. We

of

m e dic i n e

used alterations in mental status as an indicator
of subtle brain injury because children who have
abnormal Glasgow Coma Scale scores during
treatment for diabetic ketoacidosis are more
likely to have subtle cerebral edema (on magnetic resonance imaging) than those who have
normal mental status during treatment.31,38
Nonetheless, it is possible that declines in
Glasgow Coma Scale scores that occur during
treatment for diabetic ketoacidosis reflect physiological processes that are different from those
responsible for clinically apparent brain injury.
Third, statistical power may have been reduced
by the inclusion of repeat episodes, although such
a reduction would be small.
In conclusion, in this prospective, randomized
trial, neither the rate of administration nor the
sodium chloride content of intravenous fluids
significantly influenced neurologic outcomes of
diabetic ketoacidosis in children.
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